TrialScientific reports2019

Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Yani Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.